Cleveland Clinic Abu Dhabi's Fatima bint Mubarak Center leads regional effort in breast cancer recurrence study
TRIYAS_2023_ABUDAHABI Inaugurated in 2023, Fatima bint Mubarak Center addresses long-standing gaps in access to advanced genetic testing and precision oncology in the region.
The trial assesses a new anti-estrogen medication that could set a new standard of care for breast cancer following successful outcomes and regulatory approvals, positioning the Fatima bint Mubarak Center as a leader in cancer care and in addressing regional health inequities.
Abu Dhabi, United Arab Emirates. February, 2025: The Fatima bint Mubarak Center at Cleveland Clinic Abu Dhabi, part of the M42 group, becomes the first center in the GCC region to participate in a groundbreaking global therapeutic clinical trial aimed at reducing the recurrence of breast cancer. Funded by AstraZeneca, the trial is evaluating a new anti-estrogen medication that could potentially become the next standard of care for breast cancer patients, contingent on successful study results and regulatory approvals. The trial focuses on a drug from the family of Selective Estrogen Receptor Degrader (SERD), which is designed to block estrogen receptors more effectively than current medications. The study aims to compare this new drug to existing hormone therapies to determine its effectiveness in reducing cancer recurrence.
According to the World Health Organization, breast cancer is the second most common cancer worldwide and the leading cause of cancer-related mortality in women. In the UAE, breast cancer was the leading cause of cancer death in 2019, accounting for approximately 11.6% of cancer deaths annually, as reported by the Ministry of Health and Prevention.
As the first dedicated cancer center of its kind in the UAE, the Fatima bint Mubarak Center has transformed cancer care in the region through state-of-the-art innovations and advanced technologies, underscoring its commitment to providing compassionate and comprehensive care. By conducting ongoing research and pioneering clinical trials, the cancer center is actively studying the regional population to address and reduce health inequities. This approach not only enhances personalized care but also contributes to a deeper understanding of the unique health challenges in the region, paving the way for more equitable healthcare outcomes for all.
Emphasizing the significance of such trials, Dr. Stephen Grobmyer, Institute Chair of the Oncology Institute at Cleveland Clinic Abu Dhabi, said, 'Clinical trials are less common in the GCC region, which raises health equity concerns. Our participation in this breast cancer trial reflects our commitment to offering patients cutting-edge treatments while contributing to global understanding of how these treatments work across diverse populations. Therapeutic clinical trials are considered as the gold standard in oncology, providing essential evidence for new therapies that can offer hope to those who need it most. For many patients, these trials represent their best hope for accessing therapies that are not yet widely available.'
The trial, which is a phase 3 clinical study, involves approximately 5,500 participants worldwide. Participation in this trial positions the Fatima bint Mubarak Center as a leader in cancer care and global research. By offering access to cutting-edge clinical trials, the center is committed to bridging gaps in care and providing patients in the region with the most advanced treatment options.
Dr. Bassel Jallad, Staff Physician in Medical Oncology & Hematology at the Oncology Institute, added, 'Being the first site in the GCC to conduct this trial is a milestone for our region. It signifies recognition of our capabilities in conducting high-quality research and reflects the growing importance of including diverse populations in clinical trials. This trial will study a new class of anti-estrogen drugs that could significantly improve cure rates for patients with early-stage hormone receptor-positive breast cancer. Our goal is to ensure that our patients are represented in global research efforts, which is crucial for developing effective treatments tailored to the needs of our community.'
Shedding light on the trial, Dr. Eva Turgonyi, Medical Director at AstraZeneca GCC commented 'As breast cancer remains the number one cause of cancer-related mortality in the UAE, AstraZeneca is committed to reduce the risk of breast cancer recurrence and ultimately contributing to the elimination of breast cancer as a cause of death. We are delighted about the participation of UAE sites in the CAMBRIA-2 study. We are working to improve health equity and advocating inclusion of diverse population in our global clinical trials'.
Modeled on Cleveland Clinic's Taussig Cancer Center, one of the leading cancer care providers in the U.S., the Fatima bint Mubarak Center is designed to offer comprehensive cancer care in a single location. Unlike the fragmented approach usually seen, where patients must visit multiple specialists across various settings, the Fatima bint Mubarak Center coordinates care around the patient. The center employs multidisciplinary teams of physicians and nurses, each focusing on a specific area of cancer care. From the moment patients arrive, their dedicated team of specialists is with them every step of the way.
About Cleveland Clinic Abu Dhabi:
Cleveland Clinic Abu Dhabi, part of the M42 group, is a multispecialty hospital on Al Maryah Island in Abu Dhabi, UAE. Cleveland Clinic Abu Dhabi is a unique and unparalleled extension of US-based Cleveland Clinic's model of care, specifically designed to address a range of complex and critical care requirements unique to the Abu Dhabi population. Cleveland Clinic Abu Dhabi has the following Institutes and Departments: Heart, Vascular & Thoracic, Neurology, Digestive Disease, Eye, Respiratory, Critical Care, Oncology, Transplant, Surgical Subspecialties, Medical Subspecialties, Emergency Medicine, Anesthesiology, Pathology & Laboratory Medicine, Imaging, Quality & Patient Safety, Clinical & Nursing, Research and Education Departments. In all, more than 50 medical and surgical specialties are offered at Cleveland Clinic Abu Dhabi.
The campus is also home to a stand-alone and dedicated cancer center, Fatima bint Mubarak Center. The state-of-the-art, facility provides patients with access to diagnostics and treatment options through world- class facilities across 24 clinical departments that include a range of cancer subspecialties and programs: Blood Cancers, Breast Cancers, Endocrine Cancers, Gastrointestinal Cancers, Genitourinary Cancers, Gynecological Cancers, Head and Neck Cancers, Neurological Cancers, Thoracic Cancers, Ophthalmological Cancers and Soft Tissue Cancers among others.
Cleveland Clinic Abu Dhabi provides patients in the region with direct access to the world's best healthcare providers and Cleveland Clinic's unique model of care that includes state-of-the-art amenities and world- class service standards closer to home. M42 is an Abu Dhabi-based, global tech-enabled healthcare company operating at the forefront of medical advancement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mid East Info
17-05-2025
- Mid East Info
KFSHRC and Cleveland Clinic Partner to Drive Innovation in Autism and Neuroscience - Middle East Business News and Information
Riyadh King Faisal Specialist Hospital and Research Centre (KFSHRC) has entered into a Memorandum of Understanding with Cleveland Clinic, a leading non-profit academic medical center globally, to work together on clinical, operational, educational, and research initiatives involving autism and neurosciences. This strategic move highlights KFSHRC's dedication to broaden its international collaborations to achieve medical excellence and innovation in patient care. The MOU was signed at KFSHRC's Riyadh headquarters by H.E. Dr. Majid Alfayyadh, KFSHRC's Chief Executive Officer, and Dr. Tomislav Mihaljevic, Cleveland Clinic's Chief Executive Officer and President. The MOU details the parties' intention to create a long-term framework for collaboration in autism and neuroscience. This involves forming specialised project teams to jointly evaluate and prioritise potential partnership opportunities, aimed at enhancing KFSHRC's role in providing specialised healthcare. This partnership is part of KFSHRC's larger strategy to forge impactful global collaborations centred on knowledge exchange and capacity building, which support advancements in research, education, and workforce development. The initiative is aligned with the Health Sector Transformation Program, one of the Vision 2030 initiatives, which aims to ensure equitable access to high-quality healthcare with a strong emphasis on preventive care. It is noteworthy that KFSHRC has been ranked first in the Middle East and North Africa and 15th globally in the list of the world's top 250 Academic Medical Centres for the second consecutive year and has been recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, in the same year, it was ranked among the world's best 250 hospitals and included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine.
Egypt Today
19-04-2025
- Egypt Today
Egypt, Sweden discuss boosting cooperation in healthcare domains
Health Care - file CAIRO - 19 April 2025: Chairman of the Egypt Healthcare Authority Ahmed el Sobky conferred with Swedish Ambassador to Egypt Dag Juhlin-Dannfelt on horizons of cooperation and boosting partnership in the fields of healthcare between both sides. The meeting tackled mechanisms to implement twinship program with Karolinska Institute of Sweden, one of the most prominent international medical and academic institutions with an aim to exchange medical expertise under the umbrella of HUB program for international twinship that was launched by the authority to contribute to transferring and localizing international health examples in Egypt and benefiting from the advanced Swedish expertise in this field. During the meeting, Sobky lauded the efforts of former Swedish ambassador Håkan Emsgård to support health cooperation track between Egypt and Sweden. Sobky asserted the importance of fruitful partnership with the Swedish side in the fields of green transformation of hospitals, digital solutions, developing training programs in addition to cooperation with AstraZeneca company in supporting cancer patients and improving their treatment results. The authority aims at transferring advanced Swedish health system to Egypt via strategic partnership, Sobky said. He added that the Egyptian market has promising opportunities for investment in the sector of healthcare to support promoting Egyptian-Swedish relations within the framework of partnership between Egypt and the EU to achieve sustainable developmental and investment goals. Meanwhile, Juhlin-Dannfelt lauded Egypt's healthcare efforts, especially its humanitarian role in treating and supporting the Sudanese brethren.
Mid East Info
22-03-2025
- Mid East Info
Cleveland Clinic Abu Dhabi saves vision for patient with rare invasive fungal sinusitis using advanced skull-base surgery
Timely diagnosis and advanced skull base surgery preserved the patient's vision, avoided eye removal and averted life-threatening complications. Cleveland Clinic Abu Dhabi's multidisciplinary approach and cutting-edge therapies enabled successful treatment of a rare invasive fungal sinusitis. Abu Dhabi, United Arab Emirates: Cleveland Clinic Abu Dhabi, part of the M42 group, successfully saved a 57-year-old woman's eye from a rare and invasive fungal sinusitis through an extensive skull base surgery, preventing the need for orbital exenteration (eye removal). The patient had previously undergone bilateral sinus surgery at a different hospital, which led to post-operative maxillary sinusitis – a condition where the sinuses behind the cheeks became infected or inflamed after the procedure. She was later admitted to the Emergency Department of Cleveland Clinic Abu Dhabi with severe right-sided facial pain and swelling. Despite initial treatment with antibiotics and steroids, her condition deteriorated, leading to nasal congestion, changes in her sense of smell, and debilitating headaches. Further investigation, including an MRI, revealed mucosal thickening and a breakthrough in the thin bone separating her sinuses and orbital cavity, which caused the infection to get dangerously close to her eye and potentially spread further. A swab of the affected area confirmed an invasive fungal infection caused by Aspergillus; an infection caused by a type of fungus. If left untreated, the infection would have invaded deeper tissues of the orbit and possibly spread to nearby structures such as the brain, posing a significant threat to her life. A multidisciplinary team led by Dr. Mahdi Shkoukani, Department Chair for Otolaryngology Head & Neck Surgery in the Surgical Subspecialties Institute at Cleveland Clinic Abu Dhabi, quickly recognized the urgency of the patient's condition. They performed an extensive surgical debridement to remove the infected tissue, including parts of the sinuses, the medial orbital wall, and the orbital fat around the eye. Explaining the complex nature of the condition, Dr. Mahdi Shkoukani said: 'This was one of the rarest cases of sinusitis we encountered in recent years. Despite the patient being healthy and having a functioning immune system, the patient's fungal infection had progressed to a point where it posed a serious threat to her eye and brain if left untreated. The case underscores the importance of early diagnosis and rapid surgical and medical intervention for invasive fungal sinusitis. Through a complex and meticulous surgical procedure, we successfully removed all the infected tissue while preserving her vision. The multidisciplinary teamwork at Cleveland Clinic Abu Dhabi played a crucial role in achieving this positive outcome. We hope this story raises awareness about the severity of such infections and the importance of seeking immediate medical attention when symptoms persist or worsen.' Following surgery, the patient's infection subsided, and her tissues began to heal. A second procedure two days later confirmed no further fungal invasion, sparing her from orbital exenteration. She was started on antifungal medications from day one when we first suspected the infection and was closely managed by the infectious disease team. Today, her sinuses have healed and her vision remains intact. Dr. Shkoukani commented further: 'Fungi are typically harmless and naturally present in the sinuses. However, in certain conditions, they can become aggressive, spreading to surrounding tissues, including the eyes and brain. In patients with compromised immune systems, this invasion can progress rapidly, leading to a condition known as acute invasive fungal sinusitis. In immune-competent individuals, like our patient, the progression is usually slower, resulting in chronic invasive sinusitis. At Cleveland Clinic Abu Dhabi, our advanced facilities and multidisciplinary expertise enable us to manage such complex cases with precision and care.' Reflecting on her journey, the patient shared: 'I'm incredibly grateful to the team at Cleveland Clinic Abu Dhabi for their swift action and expertise. It was a terrifying experience to think I might lose my eye, but their dedication and skill saved me. I never imagined something like a sinus infection could become so dangerous, and I hope my story encourages others to seek help early if they have persistent symptoms.' This case, out of many, underscores Cleveland Clinic Abu Dhabi's expertise in complex care and its commitment to innovation and patient-centered care. The hospital continues to make a transformative impact in the lives of patients with world-class care. The hospital's Integrated Surgical Institute combines cutting-edge diagnostics and surgical expertise to address complex cases like this. Raising public awareness about symptoms such as persistent facial pain and swelling, coupled with early medical intervention, can prevent severe complications. About Cleveland Clinic Abu Dhabi: Cleveland Clinic Abu Dhabi, part of the M42 group, is a multispecialty hospital located on Al Maryah Island in Abu Dhabi, UAE. As an extension of Cleveland Clinic in the U.S., it is uniquely designed to address the complex and critical care needs of the UAE and the broader region. The hospital is organized into specialized Institutes, including Heart, Vascular & Thoracic; Neurological; Cancer; Digestive Disease; Medical Subspecialties; Integrated Surgical Subspecialties; Integrated Hospital Care; and Diagnostic. Celebrating its 10th anniversary in 2025, Cleveland Clinic Abu Dhabi is a 405-bed hospital, including 321 acute care beds, 84 critical care beds, four royal suites, and 26 operating rooms. Its state-of-the-art facilities provide patients in the region with direct access to world-class healthcare providers and Cleveland Clinic's renowned model of care. The hospital is also home to the Fatima bint Mubarak Center, a dedicated cancer center offering comprehensive diagnostics and advanced treatment across 24 clinical departments, covering a range of cancer subspecialties and programs. Committed to medical innovation, Cleveland Clinic Abu Dhabi integrates robotics across specialties, pioneers' endovascular therapy and hybrid procedures, and offers comprehensive programs in heart failure, heart transplantation, and limb salvage. Licensed by the Department of Health – Abu Dhabi as a designated research and teaching facility, Cleveland Clinic Abu Dhabi drives medical innovation through clinical trials and advanced research to enhance patient care. It is the first hospital in the UAE accredited by both the Accreditation Council for Graduate Medical Education International (ACGMEI) and the Accreditation Council for Continuing Medical Education (ACCME), offering residency and fellowship programs, undergraduate health professional training, and Continuing Medical Education (CME). M42 is a global, tech-enabled healthcare company based in Abu Dhabi, operating at the forefront of medical advancement.
